Study to Evaluate Hemodynamic Response to to a Sublingual Dose of Glyceryl Trinitrate in Subjects Receiving TA-1790, Sildenafil Citrate, and Placebo

NCT ID: NCT01616485

Last Updated: 2012-06-14

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE1

Total Enrollment

106 participants

Study Classification

INTERVENTIONAL

Study Start Date

2004-03-31

Study Completion Date

2004-05-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The objective of this study is to evaluate the hemodynamic response to a sublingual dose of glyceryl trinitrate in subjects receiving oral TA-1790, sildenafil citrate, and placebo.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Erectile Dysfunction

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

CROSSOVER

Primary Study Purpose

TREATMENT

Blinding Strategy

DOUBLE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Treatment A

TA-1790 + glyceryl trinitrate

Group Type EXPERIMENTAL

TA-1790

Intervention Type DRUG

2 TA-1790 100 mg capsules

Nitrostat

Intervention Type DRUG

glyceryl trinitrate tablet, USP 0.4 mg

Treatment B

sildenafil citrate + glyceryl trinitrate

Group Type ACTIVE_COMPARATOR

Sildenafil citrate

Intervention Type DRUG

2 sildenafil citrate 50 mg capsules

Nitrostat

Intervention Type DRUG

glyceryl trinitrate tablet, USP 0.4 mg

Treatment C

placebo + glyceryl trinitrate

Group Type PLACEBO_COMPARATOR

Placebo

Intervention Type DRUG

2 placebo capsules for TA-1790 100 mg capsules

Nitrostat

Intervention Type DRUG

glyceryl trinitrate tablet, USP 0.4 mg

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

TA-1790

2 TA-1790 100 mg capsules

Intervention Type DRUG

Sildenafil citrate

2 sildenafil citrate 50 mg capsules

Intervention Type DRUG

Placebo

2 placebo capsules for TA-1790 100 mg capsules

Intervention Type DRUG

Nitrostat

glyceryl trinitrate tablet, USP 0.4 mg

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Provide written informed consent
* Willing to comply with all study requirements and clinic schedules
* Male between 30 to 60 years of age
* Non-smoker
* No history of alcohol abuse
* Normal screening laboratory values

Exclusion Criteria

* Allergy or hypersensitive to PDE5 inhibitors
* Evidence of clinically significant disease
* Supine systolic/diastolic blood pressure level
* History of cardiovascular disease
* Previously participated in TA-1790 within the past 30 days
Minimum Eligible Age

30 Years

Maximum Eligible Age

60 Years

Eligible Sex

MALE

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

VIVUS LLC

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Craig Peterson, MS

Role: STUDY_DIRECTOR

VIVUS LLC

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

MDS Pharma Services

Phoenix, Arizona, United States

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

TA-04

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

A Study in Erectile Dysfunction
NCT01130532 COMPLETED PHASE4